Eli Lilly (NYSE: LLY) has accomplished something big over the past year. It's become the leading weight loss drug company in ...

A study of over 620,000 people found that weight gain in your 20s carries disproportionately high and lasting risks of ...

GLP-1 receptor agonists — such as semaglutide (Ozempic and Wegovy), and tirzepatide (Mounjaro and Zepbound) — have been most ...

We worked with testers, whose identities we have verified, to test the products and services mentioned in this story. Due to the private nature of individual health concerns, we have chosen to change ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By ...

In a study involving over 600,000 people, researchers at Lund University in Sweden have investigated how changes in weight ...

With nearly two-thirds (65%) of adults aged 18 and over estimated to be overweight, Nature's Best, a leading UK nutrition and ...

A doctor discusses common issues and questions around Foundayo, the oral obesity pill approved by the FDA this week.

Not all pounds you gain carry the same weight. Being overweight can lead to a host of health problems, like chronic diseases ...

Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI to deploy the technology ...

The FDA also asked Lilly to conduct a milk-only lactation study in women who have received a dose to assess concentrations of ...

Here’s how retatrutide works and how it differs from existing weight management medications.